Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer

NCT05184400 · tracked via the Priya Life Science Denmark tracker

Sponsor

Herlev and Gentofte Hospital

Phase

Observational

Started

2015-01-01

Last updated

2022-01-11

Condition(s) studied

Biliary Tract CancerCholangiocarcinomaGallbladder Cancer

Study summary

No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Histological or cytological diagnosis of BTC * Patients referred for treatment of BTC * Signed informed consent Exclusion Criteria: * None

Primary outcome measure(s)

Diagnostic accuracy (sensitivity and specificity) — Baseline
Outcome for diagnostic biomarkers. Case-control design.
Overall survival (OS) — Baseline to death or lost to follow-up, an average of 1 year
Outcome for prognostic and predictive biomarkers

Trial sites (1)

Facility	City	Region	Status
Herlev & Gentofte Hospital	Herlev	Copenhagen	Recruiting

More Herlev and Gentofte Hospital trials in Denmark

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) Active, not recruiting

ctDNA for Risk Stratification in Melanoma Active, not recruiting

Migration and Functional Outcome of DELTA Xtend Reverse Shoulder Lateralized Glenosphere Line Extension System Recruiting

Echocardiography in Men With Erectile Dysfunction Active, not recruiting

Implementation of Nutritional Efforts on Discharged Older Patients Recruiting

Other trials for the same condition

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Active, not recruiting

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05184400 on ClinicalTrials.gov ↗ ← All trials in Denmark